Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX: 6704)

Market Cap	3.09B
Revenue (ttm)	150.50M
Net Income (ttm)	-103.67M
Shares Out	95.95M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,663
Open	31.80
Previous Close	32.00
Day's Range	31.50 - 33.00
52-Week Range	28.60 - 43.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Gwo Xi Stem Cell Applied Technology Co. ,

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6704

Financial Performance

In 2023, Gwo Xi Stem Cell Applied Technology Co. ,'s revenue was 141.18 million, a decrease of -21.86% compared to the previous year's 180.67 million. Losses were -88.09 million, -21.42% less than in 2022.